Metabolic stress induces a Wnt-dependent cancer stem cell-like state transition

Cell Death and Disease

Volumn 6, Issue , 2015, Pages

  Lee, E ^a,b   Yang, J ^a,c   Ku, M ^a,b   Kim, N H ^d   Park, Y ^a   Park, C B ^d   Suh, J S ^a,c   Park, E S ^c   Yook, J I ^d   Mills, G B ^e   Huh, Y M ^a,c   Cheong, J H ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Yonsei University College of Dentistry   (South Korea)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; WNT3A PROTEIN; WNT3A PROTEIN, HUMAN;

ARTICLE; CANCER STEM CELL; CELL CLONING; CELL SELECTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; METABOLIC STRESS; PHENOTYPE; PRIORITY JOURNAL; STOCHASTIC MODEL; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTOLOGY; DRUG SCREENING; FEMALE; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOUSE; MULTICELLULAR SPHEROID; NUDE MOUSE; PATHOLOGY; PHYSIOLOGICAL STRESS; PHYSIOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL CULTURE;

ANIMALS; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASTIC STEM CELLS; SPHEROIDS, CELLULAR; STRESS, PHYSIOLOGICAL; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY; WNT3A PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942849998     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.171     Document Type: Article

References (52)

1. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011; 146: 633-644.
2. Chaffer Christine L, Marjanovic Nemanja D, Lee T, Bell G, Kleer Celina G, Reinhardt F et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013; 154: 61-74.
3. Liu S, Dontu G, Wicha MS. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res 2005; 7: 86-95.
4. Scheel C, Weinberg RA. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol 2012; 22: 396-403.
5. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741-4751.
6. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-768.
7. Magee JA, Piskounova E, Morrison S. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012; 21: 283-296.
8. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009; 138: 822-829.
9. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acd Sci USA 2011; 108: 7950-7955.
10. Yeom CJ, Goto Y, Zhu Y, Hiraoka M, Harada H. Microenvironments and cellular characteristics in the micro tumor cords of malignant solid tumors. Int J Mol Sci 2012; 13: 13949-13965.
11. Mather JP. Concise review: cancer stem cells: in vitro models. Stem Cells 2012; 30: 95-99.
12. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001; 98: 2603-2614.
13. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7: 834-846.
14. Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006; 98: 316-325.
15. Baguley BC. Multiple drug resistance mechanisms in cancer. Mol Biotechnol 2010; 46: 308-316.
16. Ponti D, Zaffaroni N, Capelli C, Daidone MG. Breast cancer stem cells: an overview. Eur J Cancer 2006; 42: 1219-1224.
17. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acd Sci USA 2003; 100: 3983-3988.
18. Alison MR, Islam S, Wright NA. Stem cells in cancer: instigators and propagators? J Cell Sci 2010; 123: 2357-2368.
19. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138: 645-659.
20. Marjanovic ND, Weinberg RA, Chaffer CL. Cell plasticity and heterogeneity in cancer. Clin Chem 2013; 59: 168-179.
21. Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J et al. Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell 2008; 134: 62-73.
22. Ni J, Cozzi PJ, Duan W, Shigdar S, Graham PH, John KH et al. Role of the EpCAM (CD326) in prostate cancer metastasis and progression. Cancer Metastasis Rev 2012; 31: 779-791.
23. Anderson ARA, Weaver AM, Cummings PT, Quaranta V. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 2006; 127: 905-915.
24. Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN. Hypoxia inducible factors in cancer stem cells. Br J Cancer 2010; 102: 789-795.
25. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007; 129: 465-472.
26. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10: 2.
27. Saijo N. Present status and problems on molecular targeted therapy of cancer. Cancer Res Treat 2012; 44: 1-10.
28. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011; 8: 97-106.
29. Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982; 31: 99-109.
30. Zhang M, Atkinson RL, Rosen JM. Selective targeting of radiation-resistant tumor-initiating cells. Proc Natl Acd Sci USA 2010; 107: 3522-3527.
31. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM. Erratum: WNT/β-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acd Sci USA 2007; 104: 618-623.
32. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A et al. The β-Catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111: 241-250.
33. Kim NH, Kim HS, Kim N-G, Lee I, Choi H-S, Li X-Y et al. p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal 2011; 4: ra71.
34. Smartt HJM, Greenhough A, Ordóñez-Morán P, Al-Kharusi M, Collard TJ, Mariadason JM et al. β-catenin negatively regulates expression of the prostaglandin transporter PGT in the normal intestinal epithelium and colorectal tumour cells: A role in the chemopreventive efficacy of aspirin. Br J Cancer 2012; 107: 1514-1517.
35. Louie E, Nik S, Chen JS, Schmidt M, Song B, Pacson C et al. Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res 2010; 12: 6.
36. Gumireddy K, Sun F, Klein-Szanto AJ, Gibbins JM, Gimotty PA, Saunders AJ et al. In vivo selection for metastasis promoting genes in the mouse. Proc Natl Acd Sci USA 2007; 104: 6696-6701.
37. Park HR, Tomida A, Sato S, Tsukumo Y, Yun J, Yamori T et al. Effect on tumor cells of blocking survival response to glucose deprivation. J Natl Cancer Inst 2004; 96: 1300-1310.
38. Morikawa K, Walker SM, Jessup JM, Fidler IJ. In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res 1988; 48: 1943-1948.
39. Podlaha O, Riester M, De S, Michor F. Evolution of the cancer genome. Trends Genet 2012; 28: 155-163.
40. Greaves M. Cancer stem cells as 'units of selection'. Evol Appl 2013; 6: 102-108.
41. Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell stem cell 2012; 10: 717-728.
42. Kang S, Bajnok L, Longo KA, Petersen RK, Hansen JB, Kristiansen K et al. Effects of Wnt signaling on brown adipocyte differentiation and metabolism mediated by PGC-1α. Mol Cell Biol 2005; 25: 1272-1282.
43. Lin CL, Wang JY, Huang YT, Kuo YH, Surendran K, Wang FS. Wnt/β-catenin signaling modulates survival of high glucose-stressed mesangial cells. J Am Soc Nephrol 2006; 17: 2812-2820.
44. Merlo LMF, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006; 6: 924-935.
45. Jovanovic J, Rønneberg JA, Tost J, Kristensen V. The epigenetics of breast cancer. Mol Oncol 2010; 4: 242-254.
46. Takebe N, Percy Ivy S. Controversies in cancer stem cells: targeting embryonic signaling pathways. Clin Cancer Res 2010; 16: 3106-3112.
47. Dawson Mark A, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012; 150: 12-27.
48. Oishi N, Wang XW. Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci 2011; 7: 517-535.
49. Zeng YA, Nusse R. Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture. Cell Stem Cell 2010; 6: 568-577.
50. Gostner JM, Fong D, Wrulich OA, Lehne F, Zitt M, Hermann M et al. Effects of EpCAM overexpression on human breast cancer cell lines. BMC Cancer 2011; 11.
51. Kalani MYS, Cheshier SH, Cord BJ, Bababeygy SR, Vogel H, Weissman IL et al. Wnt-mediated self-renewal of neural stem/progenitor cells. Proc Natl Acd Sci USA 2008; 105: 16970-16975.
52. Shenghui H, Nakada D, Morrison SJ. Mechanisms of stem cell self-renewal. Annu Rev Cell Dev 2009; 25: 377-406.